Abstract CT311: A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC)

2014 ◽  
Author(s):  
Ana B. Oton ◽  
Byoung Chul Cho ◽  
Myung-Ju Ahn ◽  
Sang-We Kim ◽  
Kirushnakumar Subramanian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Third Line Therapy ◽  
Third Line

scholarly journals Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

2018 ◽  
Vol 19 (4) ◽  
pp. 521-536 ◽  
Author(s):  
Marina Chiara Garassino ◽  
Byoung-Chul Cho ◽  
Joo-Hang Kim ◽  
Julien Mazières ◽  
Johan Vansteenkiste ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Study ◽  
Third Line
Sign in / Sign up

Export Citation Format

Share Document